Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Deutsche Biotech Innovativ AG: Barrier function of blood vessels as therapeutic target in life-threatening COVID-19 patients: Adrenomed's Antibody Adrecizumab from shows positive effect

Company: Deutsche Biotech Innovativ AG Date: 2020-08-25 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details

Media | 25 August 2020 10:58

#   

Deutsche Biotech Innovativ AG: Barrier function of blood vessels as therapeutic target in life-threatening COVID-19 patients: Adrenomed’s Antibody Adrecizumab from shows positive effect

  

DGAP-Media / 25.08.2020 / 10:58  

**Press release**

**Deutsche Biotech Innovativ AG: Barrier function of blood vessels as therapeutic target in life-threatening COVID-19 patients: Adrenomed’s Antibody Adrecizumab from shows positive effect**

**Henningsdorf, July 24, 2020 –** Adrenomed AG, an investment of Deutsche Biotech Innovativ AG (DBI AG) (WKN: A0Z25L/ ISIN: DE000A0Z25L1), today announced a peer-reviewed publication in the journal “ *Biomolecules* ” reporting on the treatment of eight life-threatening COVID-19 patients with Adrecizumab. Therapy with Adrecizumab (HAM8101) showed positive results in this limited case series. Within the observation period, seven out of eight patients survived the severe disease. This is the first treatment trial with a drug candidate that addresses the restoration of vascular integrity in extremely severe COVID-19 patients who required mechanical ventilation and for whom no other treatment option was available.

Adrecizumab is Adrenomed’s drug candidate and is currently in clinical development for the treatment of septic shock. Sepsis is an overreaction of the body’s immune system during the fight against a bacterial or viral infection, as in this case SARS-CoV-2, which leads to blood vessel permeability, severe disruption of organ function and ultimately death.

The patients were treated at the Clinic for Intensive Care Medicine, University Medical Center Hamburg-Eppendorf. In contrast to other recently published case reports, all eight patients were highly affected by pre-existing conditions such as hypertension, type 2 diabetes mellitus and obesity. At the time of treatment, all patients were mechanically ventilated due to severe acute respiratory distress syndrome (ARDS) and received vasopressors for shock therapy. Six patients experienced acute renal failure at baseline.

In this case series, seven of eight patients survived the disease. In five out of seven patients, Adrecizumab therapy resulted in an improvement in organ function within a short period of time (indicated by the SOFA score) and subsequently in a disease severity score within 12 days of administration. One patient died on day 4 due to non-treatment related severe pulmonary embolism. During the reported follow-up periods of 13 and 27 days, four patients were stable in the ICU and three were transferred to normal wards. Adrecizumab was well tolerated by all patients and again showed a good safety profile.

Ralf Jakobs, CFO of DBI AG, commented: “Even though only eight patients were included in this external study, we are pleased with the now officially published results. It strengthens our conviction regarding the chances of success of our investment Adrenomed AG”.

*This release expressly or implicitly contains certain forward-looking statements concerning the business activities of DBI AG or the performance of its shares. These forward-looking statements reflect the opinion of DBI AG as of the date of this release and involve certain known and unknown risks. DBI AG’s actual results or the development of its share price may differ materially from future results or developments implied by the forward-looking statements. DBI AG is under no obligation to update any forward-looking statements.*

  

  

  

Contact:  

Susanne Wallace

  

  

End of Media Release  

  

- - -

Issuer: Deutsche Biotech Innovativ AG  

Key word(s): Research/Technology  

  

25.08.2020 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG.  

The issuer is solely responsible for the content of this announcement.  

  

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.dgap.de  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Deutsche Biotech Innovativ AG |
|     | Neuendorfstrasse 15a |
|     | 16761 Hennigsdorf |
|     | Germany |
| Phone: | 0049 177 3166411 |
| E-mail: | s.wallace@dbi-ag.de |
| Internet: | www.dbi-ag.de |
| ISIN: | DE000A0Z25L1 |
| WKN: | A0Z25L |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt |
| EQS News ID: | 1122867 |

  

|     |     |
| --- | --- |
|     |     |
| End of News | DGAP Media |

![show this](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1122867&application_name=news&site_id=news_data)

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.